ClinicalTrials.gg
CompletedNCT05824585Updated Jul 2, 2026

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

A Phase 1 interventional study of DZD8586 in Lymphoma, Non-Hodgkin, sponsored by Dizal Pharmaceuticals. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Dizal Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 151 studies in Lymphoma, Non-Hodgkin with a site in Australia — 31 open to participants now, 64 under way, 16 of them phase 3. Lymphoma, Non-Hodgkin · Australia.

Enrollment
131st of 147
17 · median 137
Started
2023
with 11 others
Phase 1
50 of 151
14 open now
Registered
121st of 151
by date

Among the 151 studies in Lymphoma, Non-Hodgkin with a site in Australia, this one is the 131st largest by enrollment of the 147 interventional ones that give a count, is one of 12 that started in 2023, is one of 50 in phase 1, and was the 121st registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

31 of the 151 studies in Lymphoma, Non-Hodgkin with a site in Australia are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Lymphoma, Non-Hodgkin with a site in Australia, or all of them as a file.
02

Study summary

This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.

03

Conditions studied

  • Lymphoma, Non-Hodgkin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants who have provided ICF with age ≥ 18 yrs
  2. performance 0-2, no deterioration in the past 2 weeks
  3. Participants with B-NHL must have or histologically confirmed B-cell lymphoma
  4. Adequate bone marrow reserve and organ system functions
  5. Participants willing to comply with restrictions

Exclusion criteria

Exclusion Criteria:

  1. Any unresolved > Grade 1 adverse event at the time of starting study treatment with the exception of alopecia.
  2. Prior history of hematopoietic stem cell transplantation
  3. Stem cell transplantation, cell therapy, or gene therapy within 90 days. Approved small molecule therapy within 5 half-lives, small molecule therapy within 14 days. Monoclonal antibodies and antibody-drug conjugates within 28 days Radiation therapy within 1 weeks
  4. or viral vector vaccines within 4 weeks. Major surgery or significant traumatic injury within 4 weeks. History of stroke or intracranial hemorrhage within 6 months
  5. Participants with non-CNSL presence of CNS or intraocular lymphoma lesions.
  6. CNSL participants with systemic presence of lymphoma, unable to complete lumbar puncture, under systemic at a dose > 8 mg/day (dexamethasone equivalent dose) within 14 days or requiring or biologic therapy."
  7. Participants with infectious disease:
  8. cardiac disorders or abnormalities
  9. Another within 5 years prior to enrollment with the exception of adequately treated in-situ carcinoma of the cervix, uterus, basal or squamous cell carcinoma or non-melanomatous skin cancer.
  10. nausea and vomiting if not controlled by supportive therapy, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption
  11. Women who are breast feeding
  12. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    DZD8586

    Drug: DZD8586

Interventions

  • DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.

06

What researchers measure

Primary outcomes

  1. Part A: Incidence of adverse events

    Time frame: 30 days after the last dose, assessed up to 2 years

  2. Part B: Objective Response Rate assessed by investigators

    Time frame: assessed up to 2 years

Secondary outcomes

  1. Part A: Objective Response Rate assessed by investigators

    Time frame: assessed up to 2 years

  2. Part A: Plasma and CSF concentration of DZD8586

    Time frame: through discontinuation of treatment up to 10 weeks

  3. Part B: Duration of Response assessed by investigators

    Time frame: from date of first documented response until the date of documented progression, assessed up to 2 years

  4. Part B: Incidence of adverse events

    Time frame: 30 days after the last dose, assessed up to 2 years

  5. Part B: Plasma and CSF concentration of DZD8586

    Time frame: through discontinuation of treatment, assessed up to 2 years

07

Study locations

5 sites
  • Research site
    New York, New York 10065, United States
  • Research site
    Albury, New South Wales, Australia
  • Research site
    Ballarat, Victoria, Australia
  • Research site
    Melbourne, Victoria, Australia
  • Research site
    Perth, Western Australia, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Jun 2025, 25 months.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 25 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2023
First posted
Apr 21, 2023
StartActual
May 15, 2023
Primary completionActual
Jun 30, 2025
CompletionActual
Jun 30, 2025
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05824585
Responsible party
Sponsor
First posted
Apr 21, 2023
Start date
May 15, 2023
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Last update
Jul 2, 2026

Study contacts

Tianwei Zhang
study director · Dizal Pharma

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Birelentinib

Start the discussion